Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management

Expert Review of Neurotherapeutics
Dean M Wingerchuk

Abstract

There are five approved, partially effective, parenteral disease-modifying therapies for multiple sclerosis (MS), including three interferon-beta preparations, glatiramer acetate and the antineoplastic agent mitoxantrone. A sixth drug, natalizumab, was withdrawn from the market in 2005 but could return with increased safety measures. Careful surveillance for, and management of, the minor and serious adverse effects associated with these therapies in routine practice provides the best opportunity for maintaining compliance and achieving maximal therapeutic efficacy. This review outlines the strategies for the prevention, identification and management of the complications associated with administration and ongoing use of current MS therapies. These skills will become increasingly important to those caring for MS patients as contemporary treatment regimens become increasingly complex.

References

Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Feb 1, 1994·Archives of Neurology·R A Rudick
Jan 1, 1995·Duodecim; lääketieteellinen aikakauskirja·M PaneliusJ Ruutiainen
Apr 29, 1998·Brain : a Journal of Neurology·J I O'RiordanD H Miller
Feb 15, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A Bayas, P Rieckmann
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Dec 6, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C LinassierP Colombat
Feb 22, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·A WindhagenR Blasczyk
Apr 6, 2001·Neurology·O NeuhausR Hohlfeld
Aug 29, 2001·Neurology·M FilippiUNKNOWN Eurpoean/Canadian Glatiramer Acetate Study Group
Jan 18, 2002·The New England Journal of Medicine·Peter A BrexDavid H Miller
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Oct 3, 2002·Multiple Sclerosis : Clinical and Laboratory Research·R G GhalieD E De Goodkin
Nov 27, 2002·Neurology·H PanitchUNKNOWN University of British Columbia MS/MRI Research Group
Jan 3, 2003·The New England Journal of Medicine·David H MillerUNKNOWN International Natalizumab Multiple Sclerosis Trial Group
Mar 6, 2003·Multiple Sclerosis : Clinical and Laboratory Research·Jagannadha R AvasaralaElliot E Abbey
Jun 14, 2003·The Neurologist·Elliot FrohmanMichael Racke
Jun 20, 2003·Multiple Sclerosis : Clinical and Laboratory Research·Hélène ZephirPatrick Vermersch
Aug 26, 2003·Brain : a Journal of Neurology·Hassan H SalamaJingwu Zhang
Nov 26, 2003·Neurology·D S GoodinUNKNOWN Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Dec 11, 2003·Multiple Sclerosis : Clinical and Laboratory Research·D TeitelbaumR Arnon
Dec 11, 2003·Multiple Sclerosis : Clinical and Laboratory Research·Scott B PattenLuanne M Metz
Mar 25, 2004·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Catherine M EdgarPeter Green
Jun 17, 2004·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Mark S FreedmanUNKNOWN Canadian MS Working Group
Jun 30, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Helen L Tremlett, Joel Oger
Jun 30, 2004·Multiple Sclerosis : Clinical and Laboratory Research·E M FrohmanM K Racke

❮ Previous
Next ❯

Citations

Mar 2, 2010·The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses·Gabriel PardoMerriKay Oleen-Burkey
May 8, 2007·Expert Opinion on Drug Safety·Marcelo KremenchutzkyCarolina Rush
Feb 4, 2014·Mayo Clinic Proceedings·Dean M Wingerchuk, Jonathan L Carter
Oct 18, 2015·Immunologic Research·Inna TabanskyJoel N H Stern
Apr 1, 2012·International Journal of MS Care·Thomas M Stewart, Zung Vu Tran
Nov 26, 2008·Multiple Sclerosis : Clinical and Laboratory Research·R A Sawaya, M I Kanso
Apr 21, 2020·Neurology. Clinical Practice·Guadalupe Marco-MartínMaria Luisa Baeza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.